These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35524477)

  • 1. Biological activities of drug inactive ingredients.
    Zhang C; Mou M; Zhou Y; Zhang W; Lian X; Shi S; Lu M; Sun H; Li F; Wang Y; Zeng Z; Li Z; Zhang B; Qiu Y; Zhu F; Gao J
    Brief Bioinform; 2022 Sep; 23(5):. PubMed ID: 35524477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCATS Inxight Drugs: a comprehensive and curated portal for translational research.
    Siramshetty VB; Grishagin I; Nguyễn ÐT; Peryea T; Skovpen Y; Stroganov O; Katzel D; Sheils T; Jadhav A; Mathé EA; Southall NT
    Nucleic Acids Res; 2022 Jan; 50(D1):D1307-D1316. PubMed ID: 34648031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of data base structure in a successful in vitro-in vivo correlation for pharmaceutical products.
    Roudier B; Davit B; Schütz H; Cardot JM
    AAPS J; 2015 Jan; 17(1):24-34. PubMed ID: 25387995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing Dermatology Interest Groups (DIGs) in US Medical Schools: A Nationwide Survey of Student Leaders.
    Yu Z; Huang JT; Nambudiri VE
    J Drugs Dermatol; 2021 Jul; 20(7):767-770. PubMed ID: 34231994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database.
    Paulekuhn GS; Dressman JB; Saal C
    J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DrugMAP: molecular atlas and pharma-information of all drugs.
    Li F; Yin J; Lu M; Mou M; Li Z; Zeng Z; Tan Y; Wang S; Chu X; Dai H; Hou T; Zeng S; Chen Y; Zhu F
    Nucleic Acids Res; 2023 Jan; 51(D1):D1288-D1299. PubMed ID: 36243961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop.
    Zhang X; Duan J; Kesisoglou F; Novakovic J; Amidon GL; Jamei M; Lukacova V; Eissing T; Tsakalozou E; Zhao L; Lionberger R
    CPT Pharmacometrics Syst Pharmacol; 2017 Aug; 6(8):492-495. PubMed ID: 28571121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Battery of
    Rathman J; Yang C; Ribeiro JV; Mostrag A; Thakkar S; Tong W; Hobocienski B; Sacher O; Magdziarz T; Bienfait B
    Chem Res Toxicol; 2021 Feb; 34(2):601-615. PubMed ID: 33356149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial intelligence and big data facilitated targeted drug discovery.
    Liu B; He H; Luo H; Zhang T; Jiang J
    Stroke Vasc Neurol; 2019 Dec; 4(4):206-213. PubMed ID: 32030204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrimination of approved drugs from experimental drugs by learning methods.
    Tang K; Zhu R; Li Y; Cao Z
    BMC Bioinformatics; 2011 May; 12():157. PubMed ID: 21569562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raw material variability of an active pharmaceutical ingredient and its relevance for processability in secondary continuous pharmaceutical manufacturing.
    Stauffer F; Vanhoorne V; Pilcer G; Chavez PF; Rome S; Schubert MA; Aerts L; De Beer T
    Eur J Pharm Biopharm; 2018 Jun; 127():92-103. PubMed ID: 29452241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine Learning Uncovers Food- and Excipient-Drug Interactions.
    Reker D; Shi Y; Kirtane AR; Hess K; Zhong GJ; Crane E; Lin CH; Langer R; Traverso G
    Cell Rep; 2020 Mar; 30(11):3710-3716.e4. PubMed ID: 32187543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019.
    Bharate SS
    Drug Discov Today; 2021 Feb; 26(2):384-398. PubMed ID: 33221522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods.
    Neugebauer A; Hartmann RW; Klein CD
    J Med Chem; 2007 Sep; 50(19):4665-8. PubMed ID: 17705363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational pharmaceutics - A new paradigm of drug delivery.
    Wang W; Ye Z; Gao H; Ouyang D
    J Control Release; 2021 Oct; 338():119-136. PubMed ID: 34418520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting new indications for approved drugs using a proteochemometric method.
    Dakshanamurthy S; Issa NT; Assefnia S; Seshasayee A; Peters OJ; Madhavan S; Uren A; Brown ML; Byers SW
    J Med Chem; 2012 Aug; 55(15):6832-48. PubMed ID: 22780961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update of TTD: Therapeutic Target Database.
    Zhu F; Han B; Kumar P; Liu X; Ma X; Wei X; Huang L; Guo Y; Han L; Zheng C; Chen Y
    Nucleic Acids Res; 2010 Jan; 38(Database issue):D787-91. PubMed ID: 19933260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.